anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Children with type III supracondylar fractures of humerus who meet the study inclusion criteria will be invited to participate in the study by the on call orthopaedic surgeon. All patients will be required to provide informed consent. Patients will then be randomized through a random number software package and will commence immediately after confirmation of inclusion into the study. The fracture is reduced and fixed percutaneously either with crossed or lateral K wires, according to which group the subject was randomized to. Post reduction antero-posterior and lateral radiographs of the elbow are done in the operating room. Above elbow cast is applied. Radiographs are taken at follow-up visits to the clinic. The radiographs are measured to determine loss of reduction between immediate post-op films and films taken immediately prior to pin removal.
PURPOSE:To obtain a ceramic material for a living body having excellent bio- compatibility, bonded to periodontal tissue and having high toughness and high reliability, by forming glass ceramics from specific components. CONSTITUTION:Glass ceramics of a material for a living body containing staple fibers or whiskers uniformly dispersed in a glass ceramics sintered body consist of 40-70 SiO2, 15-40 Al2O3, 15-30 MgO, 70-100 SiO2+Al2O3+MgO, 0-5 CaO+SrO+BaO, 0-7 Na2O+K2O+Li2O, 0-10 TiO2+ZrO2 and 0-10 P2O5 on a wt.% basis. When the sum of SiO2, Al2O3 and MgO is 70% or less, the bending strength and toughness of a material lower. When the sum of CaO, SrO and BaO exceeds 5%, bending strength and toughness are not enhanced. Na2, K2O and Li2O promote the stability of glass to make work easy but, when the sum thereof exceeds 7%, the durability of glass ceramics is deteriorated. TiO2 and ZrO2 are added as a crystal nucleus forming agent and, when the total amount thereof exceeds 10%, melting becomes difficult and toughness is not enhanced. P2O5 is added as a crystal nucleus forming agent and enhances bio-compatibility but makes the melting of glass difficult when the content thereof is 10% or more.
Stroke is the second leading cause of death worldwide, and hypoxia is a major crisis of the brain after stroke. Therefore, providing oxygen to the brain microenvironment can effectively protect neurons from damage caused by cerebral hypoxia. However, there is a lack of timely and effective means of oxygen delivery clinically to the brain for acute cerebral hypoxia. Here, a phase-change based nano oxygen carrier is reported, which can undergo a phase change in response to increasing temperature in the brain, leading to oxygen release. The nano oxygen carrier demonstrate intracerebral oxygen delivery capacity and is able to release oxygen in the hypoxic and inflammatory region of the brain. In the acute ischemic stroke mouse model, the nano oxygen carrier can effectively reduce the area of cerebral infarction and decrease the level of inflammation triggered by cerebral hypoxia. By taking advantage of the increase in temperature during cerebral hypoxia, phase-change oxygen carrier proposes a new intracerebral oxygen delivery strategy for reducing acute cerebral hypoxia.
The room will be kept at 25-27 degrees Celsius. This is above the human thermoneutral zone. This will serve as the experimental condition.
Epidemic outbreaks of infectious diseases in conflict zones are complex threats to public health and humanitarian activities that require creativity approaches of reducing their damage. This narrative review focuses on the technology intersection with infectious disease response in conflict zones, and complexity of healthcare infrastructure, population displacement, and security risks. This narrative review explores how conflict-related destruction is harmful towards healthcare systems and the impediments to disease surveillance and response activities. In this regards, the review also considered the contributions of technological innovations, such as the improvement of epidemiological surveillance, mobile health (mHealth) technologies, genomic sequencing, and surveillance technologies, in strengthening infectious disease management in conflict settings. Ethical issues related to data privacy, security and fairness are also covered. By advisement on policy that focuses on investment in surveillance systems, diagnostic capacity, capacity building, collaboration, and even ethical governance, stakeholders can leverage technology to enhance the response to infectious disease in conflict settings and, thus, protect the global health security. This review is full of information for researchers, policymakers, and practitioners who are dealing with the issues of infectious disease outbreaks in conflicts worn areas.
Luminescent orthodontic appliances, such as brackets, archwires, bands and the like, having a luminescent pigment or mixture of luminescent pigments are described. In a preferred form, the luminescent pigment is a phosphorescent pigment comprising zinc sulfide doped with copper. The pigment gives the appliance a natural appearance in daylight and causes it to emit a greenish-white light in the dark after having been energized by an excitation light source. If desired, the luminescent orthodontic appliance may be made with a fluorescent pigment or a combination of fluorescent and phosphorescent pigments. If a fluorescent pigment is used, the bracket will exhibit a luminescence in daylight; whereas if a mixture of fluorescent and phosphorescent pigments are used, the appliance will luminesce in the dark after having been exposed to a light source, in addition to exhibiting a luminescence in the daylight. The luminescent appliances of this invention provide a fun alternative to traditional orthodontic appliances, particularly for younger patients, who can "show off" their braces to their families and friends.
BACKGROUND: Bicuspid aortic valves (BAV) are frequently associated with ascending aortic aneurysms. The etiology is incompletely understood, but genetic factors, in addition to flow perturbations, are likely involved. Since loss of contractility and elaboration of extracellular matrix in the vessel wall are features of BAV-associated aortopathy, phenotypic modulation of smooth muscle cells (SMCs) may play a role.
METHODS: Ascending aortic tissue was collected intra-operatively from 25 individuals with normal (i.e., tricuspid) aortic valves (TAV) and from 25 individuals with BAVs. For both TAV and BAV, 10 patients had non-dilated (ND) and 15 patients had dilated (D) aortas. SMCs were isolated and cultured from a subset of patients from each group. Aortic tissue and SMCs were fluorescently immunolabeled for SMC phenotypic markers (i.e., alpha-smooth muscle actin (ASMA, contractile), vimentin (synthetic) and p16INK4a and p21Cip1 (senescence). SMCs were also analyzed for replicative senescence in culture.
RESULTS: In normal-sized and dilated BAV aortas, SMCs switched from the contractile state to either synthetic or senescent phenotypes, as observed by loss of ASMA (ND: P = 0.001, D: P = 0.002) and associated increases in vimentin (ND: P = 0.03, D: P = 0.004) or p16/p21 (ND: P = 0.03, D: P<0.0001) compared to TAV. Dilatation of the aorta exacerbated SMC phenotypic switching in both BAV and TAV aortas (all P<0.05). In SMCs cultured from normal and dilated aortas, those isolated from BAV reached replicative senescence faster than those from TAV aortas (all P = 0.02). Furthermore, there was a stark inverse correlation between ASMA and cell passage number in BAV SMCs (ND: P = 0.0006, D: P = 0.01), but not in TAV SMCs (ND: P = 0.93, D: P = 0.20).
CONCLUSIONS: The findings of this study provide direct evidence from cell culture studies implying that SMCs switch from the contractile state to either synthetic or senescent phenotypes in the non-dilated BAV aorta. In cultured SMCs from both non-dilated and dilated aortas, we found that this process may precede dilatation and accompany aneurysm development in BAV. Our findings suggest that therapeutically targeting SMC phenotypic modulation in BAV patients may be a viable option to prevent or delay ascending aortic aneurysm formation.
PURPOSE: A composition containing Polygonum Cuspidatum extract or fraction or stilbene compounds derived from the extract or fraction is provided to prevent or treat common cold. CONSTITUTION: A composition for preventing or treating common cold contains Polygonum Cuspidatum extract or fraction as an active ingredient. The extract is isolated using water, low alcohol of 1-4 carbon atoms, or mixture solvent thereof. The low alcohol is methanol, ethanol, or butanol. The fraction is water fraction, ethyl acetate fraction, n-hexane fraction, or chloroform fraction. The extract or fraction contains stilbene compound of chemical formula 1 as an active ingredient. An external use skin formulation contains the composition. The external use formulation is manufactured in the form of ointments, lotions, sprays, patches, creams, powders, suspensions, or gels.
After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1 Liter flow, 30% FiO2).
BACKGROUND: Babies born via caesarean section in low-income settings face a higher risk of early-onset neonatal sepsis (EONS), which has greater mortality than late-onset sepsis. However, maternal factors contributing to EONS among caesarean-delivered babies in these settings, including Uganda, are not well documented. We determined maternal factors associated with EONS among term babies delivered by caesarian section at Mbarara Regional Referral Hospital (MRRH), southwestern Uganda.
METHODS: We conducted an unmatched case-control study at MRRH from December 2019 to March 2020. Cases were caesarean section-delivered term babies with EONS (within 72 h). Controls were caesarean section-delivered term babies without EONS. We enrolled mother-baby pairs for both groups, obtaining maternal data via structured questionnaires The diagnosis of EONS was made using the WHO Young Infant Integrated Management of Childhood Illnesses algorithm. Cases were consecutively recruited while controls were recruited by simple random sampling in a ratio of 1:2. We excluded newborns whose mothers were too ill to consent. We used multivariable logistic regression analysis to identify maternal factors associated with EONS.
RESULTS: We enrolled 52 cases and 104 controls. The mean age for the mothers was 27 (± 5.5) years. Neonates born to referred mothers had higher odds of EONS than those born to non-referred mothers (AOR = 6.2, 95% CI: 1.8-21). Additionally, decision-to-delivery time > 1 h for emergency caesarean section (AOR = 16, 95% CI: 4.2-65), antepartum hemorrhage (AOR = 8.0, 95% CI: 1.6-40), primiparity (AOR = 4.8, 95% CI: 1.1-21), and > 3 vaginal examinations after membrane rupture (AOR = 4.3, 95% CI: 1.5-12) were associated with EONS.
CONCLUSIONS: Prime gravidity, antepartum hemorrhage, multiple vaginal examinations after membrane rupture, long decision-to-delivery time, and referral status were associated with EONS among term babies delivered by caesarean section at MRRH. To reduce EONS risk, clinicians should limit post-membrane rupture vaginal exams or consider prophylactic antibiotics if multiple exams are needed. Screening babies born to primiparous women, those referred, those with antepartum hemorrhage, multiple vaginal exams after membranes rupture, and long decision-to-delivery times, could aid prompt recognition of EONS and timely interventions. Implementing standard procedures to reduce caesarean decision-to-delivery time could reduce risk for EONS in this setting.
"Pica" refers to the ingestion of non-nutritive substances by animals that would not typically consume them. The pica behavior can be utilized to investigate the internal conditions of animals' bodies. For example, rats, due to neuroanatomical reasons, cannot vomit; nevertheless, when nauseated, they ingest kaolin clay. This renders the ingestion of kaolin a practical proxy for measuring nausea in rats. The question of whether rats consume minerals other than kaolin during nauseous episodes remains unanswered. This study aims to identify a mineral better suited for detecting nausea in rats. In two experiments, nausea was induced in laboratory rats by a single dose of lithium chloride (0.15 M, 2% bw), and their mineral consumption over the 24-hour period was measured. Experiment 1 compared three minerals between rat groups: kaolin sold for nausea detection (kaolin A), kaolin for ceramics (kaolin B), and zeolite. Nauseated rats consumed all minerals, with the highest consumption occurring with kaolin B. In Experiment 2, three commercially available health soils were compared: edible kaolin, edible bentonite, and edible chalk. The most significant consumption was observed in the kaolin group, followed by the bentonite group, while nauseated rats did not consume edible chalk. These findings underscore the suitability of kaolin for nausea detection, although the extent of consumption may vary depending on the product.
Women Veterans are the fastest-growing segment of users in the Veterans Health Administration (VA). Their numbers are projected to increase by 73%, from 9.3% to 16.4%, between 2015 and 2043. Despite VA investment in improving care for women Veterans, gender disparities persist in cardiovascular (CV) and diabetes risk factor control. Also, the rate of perinatal depression among women Veterans is higher than that among civilian women, which is of particular concern given the association between perinatal depression and suicidality. Barriers to care for women Veterans include distance to VA care, rurality, competing work and caregiving responsibilities, comorbid mental health issues, and harassment on VA grounds. Improvements are still needed to increase women Veterans' access to and engagement in convenient, safe, evidence-based, patient-centered care that achieves the VA "lane of effort" of Veterans' "lifelong health, well-being, and resilience."

Since its inception in 2015, the Enhancing Mental and Physical health of Women through Engagement and Retention (EMPOWER) QUERI 1.0 team has focused on implementing gender-tailored care models for women Veteran patients. In EMPOWER 1.0 studies, women expressed preferences for gender-specific (women only) care and for virtual care options. Therefore, the EMPOWER 2.0 Impact Goal is to expand access to virtual, evidence-based, preventive lifestyle and mental health services for women Veterans with high-priority health conditions in rural and urban-isolation areas. This cluster randomized type 3 hybrid implementation-effectiveness trial will randomize up to 20 VA sites to one of two implementation strategies, the Replicating Effective Practices (REP) or Evidence-Based Quality Improvement (EBQI), to support implementation and sustainment of evidence-based practices (EBPs). The EBPs focus on preventive lifestyle and mental health care for women Veterans across VA facilities, several of which are rural, low-performing in women's health care, and/or lead sites for high reliability organization. The study team will conduct a mixed methods implementation evaluation to compare the effectiveness of REP and EBQI in terms of: (a) improved access to and rates of engagement in virtual preventive lifestyle and mental health services and improved VA performance metrics for virtual and telehealth care delivery and related clinical outcomes for women Veterans; (b) progression along the Stages of Implementation Completion; (c) adaptation, sense-making, and experiences of EBP implementation among multilevel stakeholders; and (d) cost and return on investment.

On 8/15/23, as part of our 12 month registration update we are correcting the primary outcomes to accurately reflect the randomized trial and analyses design. The cluster randomized trial will evaluate the effectiveness of two implementation strategies (REP and EBQI) in implementing evidence-based practices (EBPs) for preventive services. Although we are implementing three evidence-based practices (DPP, TLC and ROSE), the EBPs are combined for each of the trial's two primary outcomes (access and engagement).
Thefruits of Gleditsia sinensis Lam. have been utilized to treat inflammatory diseases in China. Echinocystic acid (EA), one pentacyclic triterpenoid isolated from thefruits of G. sinensis, exhibits an anti-inflammatory effect. However, its anti-sepsis activity and mechanism of action, especially the protective effect against sepsis-associated acute kidney injury (SA-AKI), are not investigated yet. This study is to explore the efficacy and potential mechanism of EA on SA-AKI. EA elevated the function of multiple organs and effectively reduced the increased inflammation and apoptosis of kidney tissue and HK-2 cells. DARTS, CETSA, and molecular docking experiments revealed that EA could directly bind to protein tyrosine phosphatase 1B (PTP1B), a widespread prototype non-receptor tyrosine phosphatase. Collectively, EA can alleviate murine SA-AKI though restraining inflammation and apoptosis and may be a potential natural drug for remedying SA-AKI.
A process for preparing an adrenal gland active stimulating substance in which pituitary glands are extracted with a solvent and a concentrate of the active substance with posterior pituitary contaminants therein obtained, is characterised by the fact that the concentrate is subjected to acid hydrolysis to an extent of at least equal to boiling the acid concentrate solution at a pH of 1.5 for 2 1/2 hours.  In one example, frozen hog pituitary glands are ground with ice, treated with aqueous acetone and hydrochloric acid and rapidly thawed (20 minutes).  The pH is adjusted to 1.5, agitated for 1 hour with 78 per cent acetone allowed to settle and centrifuged. The residue is treated with aqueous HCl to pH 1.42, then with acetone and is centrifuged. The combined centrifugates treated with acetone to an acetone concentration of 92 per cent are allowed to settle at 5 DEG  C. for 2 days and the precipitate dried.  The powder is extracted with M/10 dibasic sodium phosphate at pH 7.7, temperature 5 DEG  C., and centrifuged.  The extraction step is repeated twice. Ammonium sulphate is added to the combined extracts having a pH 6.95 to 50 per cent saturation, the precipitate settled at -5 DEG  C. and the precipitate centrifuged.  The precipitate is suspended in distilled water and dialyzed.  The dialyzed adrenocorticotrophic material is adjusted to pH 1.3 with HCl and boiled at 100 DEG  C. for 2 1/2 hours.  After cooling and adjustment of pH to 8.1, the liquid is dialyzed against distilled water and the dialyzed solution lyophilized to a dry powder having a potency of 230 per cent of standard, oxytocin content 0.02 m /mg and vasopressor 0.06 m /mg. The rate of rapid thawing prior to extraction is preferably from 20 minutes to one hour.  In the extraction step, the dibasic sodium phosphate may be replaced by sodium chloride, ammonium sulphate or monosodium phosphate.  Sodium chloride may replace the ammonium sulphate in the ammonium sulphate precipitation step.  The dialysis step may be replaced by a pH precipitation step.  The whole pituitary glands or the anterior pituitary glands of the hog, sheep, cow or whale may be used.
A coated pharmaceutical composition comprises (1) a nucleus containing a drug and adjuvants, coated in sequence with (2) a layer of an acid-soluble coating material which is resistant both to alkalis and intestinal juices, (3) a layer of a hydrophilic substance and (4) a layer of an alkali-soluble coating material which is resistant to acid and to gastric juices.  Specified drugs are emetine, dehydro-emetine, their hydrochlorides and complexes with bismuth iodide, antimony potassium tartrate, acetylsalicylic acid, sodium or calcium acetylsalicylate, sodium salicylate, p-amino-salicylic acid or sodium or calcium p-amino salicylate. Specified acid-soluble coating materials are basic amino-containing polyelectrolytes e.g. amino-containing polyacrylates or methacrylates (especially polymers of aminoalkyl esters of acrylic or methacrylic acids), amino-containing polysaccharides (especially benzylamino-methyl cellulose, acetyl cellulose-p-amino-benzoate, cellulose acetate diethyl aminoacetate), amino-containing sugar derivatives (especially sucrose p-amino-benzoate, mannibol p-amino-benzoate and dodecyl amine N-lactoside), and polyvinyl derivatives having basic amino groups (especially polyvinyl pyridine, polyvinyl piperidyl) acetacetal, co-polymers of vinyl pyridine and styrene, and vinyl-diethylamino/vinyl acetate copolymers).  Specified alkali-soluble coating materials are film-forming polyelectrolytes containing carboxyl groups e.g. natural lacquers especially keratin, shellac; cellulose esters containing carboxyl groups (especially acetyl-phthalyl cellulose, acetyl-succinyl cellulose), carboxyl-containing copolymers containing mallic acid or anhydride as acidic component especially co-polymers of styrene and maleic anhydride, styrene/acrylic acid and the butyl partial ester of maleic acid, maleic anhydride and vinyl methyl ether) and carboxyl-containing co-polymers with acrylic or methacrylic acid as acidic component (especially copolymers of styrene and methacrylic acid).  The hydrophilic substance may consist of sugar syrups (with or without mucilages) or solutions of solid polyethyleneglycols, and it may also be used to form an external sealing layer, optionally with colouring materials.  The porosity of the coating layers can be reduced by incorporating therein solid materials e.g. talc, pigments, calcium stearate or magnesium stearate.  The diffusion of the active drug through the alkali-resistant layer can be regulated by incorporating into the nucleus water-insoluble and/or alkali-insoluble materials as well as slowly- or non-digestible inert substances e.g. barium sulphate, Ca3Po4, CaCo3, high melting waxes, zein, or hydrogenated castor oil.  Multiple layers of either one or both types of alkali- and acid-soluble coating materials may be used, the intermediate hydrophilic layer separating successive layers. Medicaments, which may be the same or different from those present in the nucleus, may be incorporated in the intermediate hydrophilic layers.